X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (17) 17
humans (17) 17
adult (13) 13
index medicus (11) 11
middle aged (11) 11
male (10) 10
hepatitis (8) 8
ribavirin (8) 8
treatment outcome (8) 8
adolescent (7) 7
aged (7) 7
cervical cancer (7) 7
drug therapy, combination (7) 7
clinical trials (6) 6
hepatitis c, chronic - drug therapy (6) 6
human papillomavirus (6) 6
human papillomavirus recombinant vaccine quadrivalent, types 6, 11, 16, 18 (6) 6
infections (6) 6
interferon (6) 6
internal medicine (6) 6
medicine, general & internal (6) 6
papillomavirus infections - prevention & control (6) 6
abridged index medicus (5) 5
benzofurans - administration & dosage (5) 5
follow-up studies (5) 5
hepatitis c (5) 5
hepatitis c, chronic - complications (5) 5
imidazoles - administration & dosage (5) 5
infection (5) 5
mortality (5) 5
papillomavirus infections (5) 5
prevention (5) 5
quinoxalines - administration & dosage (5) 5
vaccines (5) 5
young-women (5) 5
cirrhosis (4) 4
drug administration schedule (4) 4
drug therapy (4) 4
efficacy (4) 4
gastroenterology & hepatology (4) 4
health aspects (4) 4
hepacivirus - genetics (4) 4
ribonucleic acid--rna (4) 4
sofosbuvir (4) 4
uterine cervical neoplasms - prevention & control (4) 4
young adult (4) 4
age factors (3) 3
alphapapillomavirus (3) 3
antiviral agents - administration & dosage (3) 3
cancer (3) 3
care and treatment (3) 3
cervical intraepithelial neoplasia (3) 3
comparative studies (3) 3
hepacivirus - drug effects (3) 3
hepatitis c virus (3) 3
hpv (3) 3
immunization (3) 3
medical and health sciences (3) 3
medicin och hälsovetenskap (3) 3
papillomaviridae - immunology (3) 3
papillomavirus vaccines (3) 3
papillomavirus vaccines - adverse effects (3) 3
particle vaccine (3) 3
randomized controlled-trial (3) 3
treatment-experienced patients (3) 3
treatment-naive (3) 3
united states (3) 3
vaccine (3) 3
viral load (3) 3
women (3) 3
aged, 80 and over (2) 2
antibodies, viral - blood (2) 2
antiviral agents (2) 2
basic medicine (2) 2
benzofurans - therapeutic use (2) 2
cervical intraepithelial neoplasia - prevention & control (2) 2
cervix uteri - virology (2) 2
child (2) 2
combination therapy (2) 2
comorbidity (2) 2
cost-effectiveness (2) 2
dose-response relationship, drug (2) 2
double-blind (2) 2
double-blind method (2) 2
elbasvir mk-8742 (2) 2
epidemiology (2) 2
genital warts (2) 2
genotype & phenotype (2) 2
genotype 1 infection (2) 2
genotypes (2) 2
grazoprevir mk-5172 (2) 2
hcv (2) 2
hcv ns5a inhibitor (2) 2
health facilities (2) 2
hepatitis c - drug therapy (2) 2
hepatitis c, chronic - diagnosis (2) 2
hiv infections - complications (2) 2
imidazoles - therapeutic use (2) 2
immunology (2) 2
infectious diseases (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10003, pp. 1537 - 1545
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1087 - 1097
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1075 - 1086
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9679, pp. 1949 - 1957
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2015, Volume 2, Issue 8, pp. e319 - e327
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9574, pp. 1693 - 1702
Journal Article
Gerontology & geriatric medicine, ISSN 2333-7214, 01/2019, Volume 5, p. 2333721418817398
In elderly individuals aged ≥65 years with hepatitis C virus (HCV) infection, efficacious and safe HCV therapy is complicated by frequent comorbidities and... 
Journal Article
Value in Health, ISSN 1098-3015, 2009, Volume 12, Issue 5, pp. 697 - 707
Abstract Background The risk of infection with human papillomavirus (HPV) increases with age. Answering the question of which age groups are appropriate to... 
Internal Medicine | herd immunity | condylomata acuminata | uterine cervical neoplasms | vaccines | theoretical models | human papillomavirus | cost-effectiveness analysis | disease transmission | nonlinear dynamics | cervical intraepithelial neoplasia | Cost-effectiveness analysis | Herd immunity | Nonlinear dynamics | Human papillomavirus | Disease transmission | Cervical intraepithelial neoplasia | Condylomata acuminata | Uterine cervical neoplasms | Theoretical models | Vaccines | UNITED-STATES | COST-EFFECTIVENESS | INTERNATIONAL INCIDENCE RATES | QUADRIVALENT VACCINE | HUMAN-PAPILLOMAVIRUS VACCINATION | PARTICLE VACCINE | HEALTH CARE SCIENCES & SERVICES | INVASIVE CERVICAL-CANCER | ECONOMIC-IMPACT | HEALTH POLICY & SERVICES | INFECTION | ECONOMICS | HEALTH | Models, Econometric | Age Factors | United States | Humans | Middle Aged | Mass Vaccination - economics | Condylomata Acuminata - prevention & control | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | Young Adult | Aged, 80 and over | Uterine Cervical Neoplasms - economics | Adult | Condylomata Acuminata - economics | Female | Child | Quality-Adjusted Life Years | Papillomavirus Vaccines - economics | Costs and Cost Analysis | Papillomavirus Vaccines - therapeutic use | Uterine Cervical Neoplasms - prevention & control | Papillomavirus Infections - economics | Papillomavirus Infections - prevention & control | Cost-Benefit Analysis | Adolescent | Aged | Warts | Vaccination | Public health | Cervical cancer
Journal Article
Journal Article
Hepatology, ISSN 0270-9139, 09/2017, Volume 66, Issue 3, pp. 736 - 745
Journal Article
Journal Article